Targeting the complement cascade: novel treatments coming down the pike

Kidney International

Volumn 90, Issue 4, 2016, Pages 746-752

  Thurman, Joshua M ^a   Le Quintrec, Moglie ^b  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b LAPEYRONIE HOSPITAL   (France)

Author keywords

complement; glomerulonephritis; inflammation

Indexed keywords

ACH 3856; ACH 4100; ACH 4471; AVACOPAN; COMPLEMENT; COMPLEMENT COMPONENT C1S; COMPLEMENT COMPONENT C1S INHIBITOR; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3B RECEPTOR; COMPLEMENT COMPONENT C5; COMPLEMENT COMPONENT C5A RECEPTOR; COMPLEMENT FACTOR D; COMPLEMENT FACTOR H; COMPLEMENT INHIBITOR; COMPSTATIN; ECULIZUMAB; LAMPALIZUMAB; MENINGOCOCCUS VACCINE; MIROCOCEPT; MONOCLONAL ANTIBODY; PLACEBO; RECOMBINANT PROTEIN; SMALL INTERFERING RNA; TNT 009; TT 30; UNCLASSIFIED DRUG;

AGE RELATED MACULAR DEGENERATION; ANCA ASSOCIATED VASCULITIS; ANGIONEUROTIC EDEMA; ANTIBODY MEDIATED REJECTION; ARTICLE; COMPLEMENT ACTIVATION; COMPLEMENT DEFICIENCY; COMPLEMENT INHIBITION; COMPLEMENT SYSTEM; DRUG HALF LIFE; DRUG MECHANISM; DRUG TARGETING; END STAGE RENAL DISEASE; GENETIC POLYMORPHISM; HEMOLYTIC UREMIC SYNDROME; HUMAN; IMMUNE RESPONSE; IMMUNOGLOBULIN A NEPHROPATHY; INFECTION RISK; KIDNEY ALLOGRAFT REJECTION; KIDNEY DISEASE; KIDNEY GRAFT REJECTION; MENINGOCOCCOSIS; NONHUMAN; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); SINGLE DRUG DOSE; ADAPTIVE IMMUNITY; CHOROIDITIS; DRUG EFFECTS; IMMUNOLOGY; INNATE IMMUNITY; KIDNEY; KIDNEY DISEASES; METABOLISM; RECURRENT DISEASE;

ADAPTIVE IMMUNITY; ANTIBODIES, MONOCLONAL, HUMANIZED; CHOROIDITIS; COMPLEMENT ACTIVATION; COMPLEMENT INACTIVATING AGENTS; COMPLEMENT SYSTEM PROTEINS; HUMANS; IMMUNITY, INNATE; KIDNEY; KIDNEY DISEASES; RECURRENCE;

EID: 84977495983     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1016/j.kint.2016.04.018     Document Type: Short Survey

References (57)

1. Betjes, M.G., Immune cell dysfunction and inflammation in end-stage renal disease. Nat Rev Nephrol 9 (2013), 255–265.
2. Thurman, J.M., Complement in kidney disease: core curriculum 2015. Am J Kidney Dis 65 (2015), 156–168.
3. Endo, M., Ohi, H., Ohsawa, I., et al. Glomerular deposition of mannose-binding lectin (MBL) indicates a novel mechanism of complement activation in IgA nephropathy. Nephrol Dial Transplant 13 (1998), 1984–1990.
4. Zipfel, P.F., Skerka, C., Complement regulators and inhibitory proteins. Nat Rev Immunol 9 (2009), 729–740.
5. Le Quintrec, M., Roumenina, L., Noris, M., et al. Atypical hemolytic uremic syndrome associated with mutations in complement regulator genes. Semin Thromb Hemost 36 (2010), 641–652.
6. Servais, A., Noel, L.H., Roumenina, L.T., et al. Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney Int 82 (2012), 454–464.
7. Watanabe, H., Garnier, G., Circolo, A., et al. Modulation of renal disease in MRL/lpr mice genetically deficient in the alternative complement pathway factor B. J Immunol 164 (2000), 786–794.
8. Xiao, H., Schreiber, A., Heeringa, P., et al. Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies. Am J Pathol 170 (2007), 52–64.
9. Volanakis, J.E., Barnum, S.R., Giddens, M., et al. Renal filtration and catabolism of complement protein D. N Engl J Med 312 (1985), 395–399.
10. Legendre, C.M., Licht, C., Muus, P., et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 368 (2013), 2169–2181.
11. Zuber, J., Quintrec, M.L., Krid, S., et al. Eculizumab for Atypical Hemolytic Uremic Syndrome Recurrence in Renal Transplantation. Am J Transplant 12 (2012), 3337–3354.
12. Ardissino, G., Testa, S., Possenti, I., et al. Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome: a report of 10 cases. Am J Kidney Dis 64 (2014), 633–637.
13. Le Quintrec, M., Lionet, A., Kandel, C., et al. Eculizumab for treatment of rapidly progressive C3 glomerulopathy. Am J Kidney Dis 65 (2015), 484–489.
14. Vivarelli, M., Emma, F., Treatment of C3 glomerulopathy with complement blockers. Semin Thromb Hemost 40 (2014), 472–477.
15. Pickering, M.C., Ismajli, M., Condon, M.B., et al. Eculizumab as rescue therapy in severe resistant lupus nephritis. Rheumatology. (Oxford) 54 (2015), 2286–2288.
16. Radhakrishnan, S., Lunn, A., Kirschfink, M., et al. Eculizumab and refractory membranoproliferative glomerulonephritis. N Engl J Med 366 (2012), 1165–1166.
17. Stegall, M.D., Diwan, T., Raghavaiah, S., et al. Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am J Transplant 11 (2011), 2405–2413.
18. Rosenblad, T., Rebetz, J., Johansson, M., et al. Eculizumab treatment for rescue of renal function in IgA nephropathy. Pediatr Nephrol 29 (2014), 2225–2228.
19. Skattum, L., van Deuren, M., van der Poll, T., et al. Complement deficiency states and associated infections. Mol Immunol 48 (2011), 1643–1655.
20. Kelly, R.J., Hill, A., Arnold, L.M., et al. Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival. Blood 117 (2011), 6786–6792.
21. Zuber, J., Fakhouri, F., Roumenina, L.T., et al. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nature Rev Nephrol 8 (2012), 643–657.
22. Licht, C., Greenbaum, L.A., Muus, P., et al. Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. Kidney Int 87 (2015), 1061–1073.
23. Zuber, J., Le Quintrec, M., Morris, H., et al. Targeted strategies in the prevention and management of atypical HUS recurrence after kidney transplantation. Transplant Rev (Orlando) 27 (2013), 117–125.
24. Vernon, K.A., Goicoechea de Jorge, E., Hall, A.E., et al. Acute presentation and persistent glomerulonephritis following streptococcal infection in a patient with heterozygous complement factor H-related protein 5 deficiency. Am J Kidney Dis 60 (2012), 121–125.
25. Schutte, M., DiCamelli, R., Murphy, P., et al. Effects of anesthesia, surgery and inflammation upon host defense mechanisms. I. Effects upon the complement system. Int Arch Allergy Appl Immunol 48 (1975), 706–720.
26. Nester, C., Stewart, Z., Myers, D., et al. Pre-emptive eculizumab and plasmapheresis for renal transplant in atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol 6 (2011), 1488–1494.
27. Weitz, M., Amon, O., Bassler, D., et al. Prophylactic eculizumab prior to kidney transplantation for atypical hemolytic uremic syndrome. Pediatr Nephrol 26 (2011), 1325–1329.
28. Hill, A., Hillmen, P., Richards, S.J., et al. Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria. Blood 106 (2005), 2559–2565.
29. Ricklin, D., Hajishengallis, G., Yang, K., et al. Complement: a key system for immune surveillance and homeostasis. Nat Immunol 11 (2010), 785–797.
30. Taylor, P.R., Carugati, A., Fadok, V.A., et al. A hierarchical role for classical pathway complement proteins in the clearance of apoptotic cells in vivo. J Exp Med 192 (2000), 359–366.
31. Pettigrew, H.D., Teuber, S.S., Gershwin, M.E., Clinical significance of complement deficiencies. Ann N Y Acad Sci 1173 (2009), 108–123.
32. Sekine, H., Reilly, C.M., Molano, I.D., et al. Complement component C3 is not required for full expression of immune complex glomerulonephritis in MRL/lpr mice. J Immunol 166 (2001), 6444–6451.
33. Coleman, T.H., Forristal, J., Kosaka, T., et al. Inherited complement component deficiencies in membranoproliferative glomerulonephritis. Kidney Int 24 (1983), 681–690.
34. Thurman, J.M., Lenderink, A.M., Royer, P.A., et al. C3a is required for the production of CXC chemokines by tubular epithelial cells after renal ischemia/reperfusion. J Immunol 178 (2007), 1819–1828.
35. Coulthard, L.G., Woodruff, T.M., Is the complement activation product C3a a proinflammatory molecule? Re-evaluating the evidence and the myth. J Immunol 194 (2015), 3542–3548.
36. Wenderfer, S.E., Wang, H., Ke, B., et al. C3a receptor deficiency accelerates the onset of renal injury in the MRL/lpr mouse. Mol Immunol 46 (2009), 1397–1404.
37. Li, L., Yin, Q., Tang, X., et al. C3a receptor antagonist ameliorates inflammatory and fibrotic signals in type 2 diabetic nephropathy by suppressing the activation of TGF-beta/smad3 and IKBalpha pathway. PLoS One, 9, 2014, e113639.
38. Tang, Z., Lu, B., Hatch, E., et al. C3a mediates epithelial-to-mesenchymal transition in proteinuric nephropathy. J Am Soc Nephrol 20 (2009), 593–603.
39. Nishimura, J., Yamamoto, M., Hayashi, S., et al. Genetic variants in C5 and poor response to eculizumab. N Engl J Med 370 (2014), 632–639.
40. Shaughnessy, A.F., Monoclonal antibodies: magic bullets with a hefty price tag. BMJ, 345, 2012, e8346.
41. McCamish, M., Woollett, G., Worldwide experience with biosimilar development. MAbs 3 (2011), 209–217.
42. Mocsai, A., Kovacs, L., Gergely, P., What is the future of targeted therapy in rheumatology: biologics or small molecules?. BMC Med, 12, 2014, 43.
43. Cicardi, M., Aberer, W., Banerji, A., et al. Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group. Allergy 69 (2014), 602–616.
44. Vo, A.A., Zeevi, A., Choi, J., et al. A phase I/II placebo-controlled trial of C1-inhibitor for prevention of antibody-mediated rejection in HLA sensitized patients. Transplantation 99 (2015), 299–308.
45. Viglietti, D., Gosset, C., Loupy, A., et al. C1-inhibitor in acute antibody-mediated rejection non-responsive to conventional therapy in kidney transplant recipients: a pilot study. Am J Transplant 16 (2016), 1596–1603.
46. Ricklin, D., Lambris, J.D., Progress and trends in complement therapeutics. Adv Exp Med Biol 735 (2013), 1–22.
47. Le, K.N., Gibiansky, L., van Lookeren Campagne, M., et al. Population pharmacokinetics and pharmacodynamics of lampalizumab administered intravitreally to patients with geographic atrophy. CPT Pharmacometrics Syst Pharmacol 4 (2015), 595–604.
48. Weisman, H.F., Bartow, T., Leppo, M.K., et al. Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science 249 (1990), 146–151.
49. Lazar, H.L., Bokesch, P.M., van Lenta, F., et al. Soluble human complement receptor 1 limits ischemic damage in cardiac surgery patients at high risk requiring cardiopulmonary bypass. Circulation 110 (2004), II274–II279.
50. Zhang, Y., Nester, C.M., Holanda, D.G., et al. Soluble CR1 therapy improves complement regulation in C3 glomerulopathy. J Am Soc Nephrol 24 (2013), 1820–1829.
51. Patel, H., Smith, R.A., Sacks, S.H., et al. Therapeutic strategy with a membrane-localizing complement regulator to increase the number of usable donor organs after prolonged cold storage. J Am Soc Nephrol 17 (2006), 1102–1111.
52. Risitano AM, Storek M, Sahelijo L, et al. Safety and pharmacokinetics of the complement inhibitor TT30 in a phase I trial for untreated PNH patients. Paper presented at: American Society of Hematology 57th Annual Meeting & Exposition. December 4–8, 2015; Orlando, FL.
53. Qu, H., Ricklin, D., Bai, H., et al. New analogs of the clinical complement inhibitor compstatin with subnanomolar affinity and enhanced pharmacokinetic properties. Immunobiology 218 (2013), 496–505.
54. Zhang, Y., Shao, D., Ricklin, D., et al. Compstatin analog Cp40 inhibits complement dysregulation in vitro in C3 glomerulopathy. Immunobiology 220 (2015), 993–998.
55. Jayne DRW, Bruchfeld A, Schaier M, et al. Phase 2 randomised trial of oral C5a receptor antagonist Ccx168 in ANCA-associated renal vasculitis. Paper presented at: 51st ERA-EDTA Congress. May 31–June 3, 2014; Amsterdam, The Netherlands.
56. Hill A, Taubel J, Bush J, et al. Subcutaneously administered investigational RNAi therapeutic (ALN-CC5) targeting complement C5 for treatment of PNH and complement-mediated diseases: interim phase 1 study results. Paper presented at: American Society of Hematology 57th Annual Meeting & Exposition. December 4–8, 2015; Orlando, FL.
57. Maillard, N., Wyatt, R.J., Julian, B.A., et al. Current understanding of the role of complement in IgA nephropathy. J Am Soc Nephrol 26 (2015), 1503–1512.